This work will provide a historical perspective on tumor immunotherapy, discuss fundamental mechanisms of failed tumor rejection, look at passive strategies to boost anti-tumor immunity, as well as have an in-depth look at active strategies to boost anti-tumor immunity.
This work will provide a historical perspective on tumor immunotherapy, discuss fundamental mechanisms of failed tumor rejection, look at passive strategies to boost anti-tumor immunity, as well as have an in-depth look at active strategies to boost anti-tumor immunity.
Introduction.- Historical Perspectives and Current Trends in Cancer Immunotherapy.- T cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment.- Adoptive T Cell Transfer.- Dendritic Cell-Based Cancer Immunotherapy: Achievements and novel concepts.- Peptide and Protein-based Cancer Vaccines.- Antigen Targeting to Dendritic Cells for Cancer Immunotherapy.- Cytokines in the Treatment of Cancer.- Immune Co-signaling to Treat Cance.- Managing Regulatory T cells.- Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and therapeutic perspectives .- Antibodies as Cancer Immunotherapy.- Targeted Toxins in Cancer Immunotherapy.- Miscellaneous Approaches and Considerations: TLR agonists and other inflammatory agents, anti-chemokine agents, infectious agents, tumor stroma targeting, age and sex effects, and miscellaneous small molecules.- Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies.- Monitoring Antigen-Specific Responses in Clinical Trials of Immunotherapy.- Index
Introduction.- Historical Perspectives and Current Trends in Cancer Immunotherapy.- T cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment.- Adoptive T Cell Transfer.- Dendritic Cell-Based Cancer Immunotherapy: Achievements and novel concepts.- Peptide and Protein-based Cancer Vaccines.- Antigen Targeting to Dendritic Cells for Cancer Immunotherapy.- Cytokines in the Treatment of Cancer.- Immune Co-signaling to Treat Cance.- Managing Regulatory T cells.- Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and therapeutic perspectives .- Antibodies as Cancer Immunotherapy.- Targeted Toxins in Cancer Immunotherapy.- Miscellaneous Approaches and Considerations: TLR agonists and other inflammatory agents, anti-chemokine agents, infectious agents, tumor stroma targeting, age and sex effects, and miscellaneous small molecules.- Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies.- Monitoring Antigen-Specific Responses in Clinical Trials of Immunotherapy.- Index
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826